---
document_datetime: 2025-12-17 15:35:57
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trumenba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trumenba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9410935
conversion_datetime: 2025-12-27 09:45:26.926027
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Trumenba

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 17/12/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309515   | PRODUCTS - C.I.z Other variation - Accepted To include the compliance statement on the agreed PIP EMA/PE/0000254741. In addition the MAH has also taken the opportunity to remove the statement referring to the deferral of the obligation to submit study results in one or more subsets of the paediatric population in Section 5.1 of the SmPC.                                                                                                                                                                                                                                                                                                                                                               |            |     |                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type II / | This was an application for a group of variations. B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant | 18/09/2025 | N/A | EMA/VR/0000284832 |

<div style=\"page-break-after: always\"></div>

|                                       | quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place -   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000246802 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000247141 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of an updated RMP version 9.0 in order to propose the removal of 'Use in co- administration with MMR and pneumococcal vaccines' as missing information from the safety concerns listed in the RMP and consequently, removal of the associated additional pharmacovigilance activity, study C3511006 (a Phase 3, randomized, controlled, open-label trial to assess the safety, tolerability, and immunogenicity of MenABCWY in healthy participants 12 to <24 months of age, and when administered concomitantly with MMR and pneumococcal vaccine in healthy participants â‰¥12 to <16 | 10/04/2025 | N/A |
|                                       | months of age).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000261831   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To update sections 2 and 4.4 of the SmPC and sections 2 and 6 of the Package Leaflet with excipient information for polysorbate 80 in line with the Annex to the European Commission Guideline for 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668) - Revision 4. Minor amendments to SmPC and the Package Leaflet are proposed. The MAH also took the opportunity to make some editorial changes including the URL for Appendix V and removing 'United Kingdom (Northern Ireland)' from the list of local representatives in accordance with QRD template version 10.4 as well as updating the contact details for the local representative for Ireland.   | 10/04/2025   | SmPC and PL   |                                                                                                                                                                                                                                                                                             |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248484              | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |              |               | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing meningococcal group B vaccine (recombinant, adsorbed) remains unchanged and therefore recommends the maintenance of the marketing authorisation. |